Edition:
United States

Oasmia Pharmaceutical AB (OASM.ST)

OASM.ST on Stockholm Stock Exchange

6.35SEK
11:29am EDT
Change (% chg)

-0.20kr (-3.05%)
Prev Close
6.55kr
Open
6.55kr
Day's High
6.60kr
Day's Low
6.35kr
Volume
379,664
Avg. Vol
863,463
52-wk High
14.45kr
52-wk Low
4.78kr

Latest Key Developments (Source: Significant Developments)

Karo Pharma says have sold Oasmia shares consisting "down payment" for KB 9520 project
Friday, 3 Mar 2017 04:00am EST 

Karo Pharma AB : Says board decided on Feb. 2 to sell Oasmia shares consisting "down payment" for KB 9520 project . Says shares are sold and the board will propose the AGM on May 11 to distribute the value of the shares to its shareholders .Says chairman Anders Lonner was not part of decision as he was an insider in Oasmia.  Full Article

Oasmia Q3 operating loss deepens
Friday, 3 Mar 2017 02:15am EST 

Oasmia Pharmaceutical AB : Q3 consolidated net sales amounted to TSEK 36 compared to TSEK 6,043 in Q3 previous year . Q3 operating loss was TSEK 34,861 compared to a loss of TSEK 23,245 in Q3 previous year . Says efficiency programme initiated at end of 2016 is proceeding according to plan .Says regarding further financing of operation until company can generate revenues in form of sales, royalties, milestones etc. And thereby becomes fully financed on its own merits, there are several alternative solutions.  Full Article

Oasmia issues comments on chairman resignation
Wednesday, 1 Mar 2017 02:30am EST 

Oasmia Pharmaceutical AB (Publ) : Oasmia makes clarification regarding chairman Anders Lonner's withdrawal from Board Of Directors . Says withdrawal must be viewed against backdrop that Oasmia in no way has been able to accept Mr Lonner's actions and demands he has made after he was elected chairman .Lonner was elected chairman just over 3 months ago.  Full Article

Oasmia Pharma says to move veterinary assets to United States
Monday, 23 Jan 2017 02:40am EST 

Oasmia Pharmaceutical : Says announces strategic move to bolster efforts for its Veterinary Division . Says plans to move all of company's veterinary assets including Paccal Vet and Doxophos Vet, to United States for further development and commercialization efforts . Says key objective within veterinary medicine is to successfully transition the products on a broader scale to a larger number of veterinary clinics . Clinical program with Doxophos Vet is ongoing, with the expectation to communicate the results from a proof of concept study during the spring of 2017 . Says anticipates that changing the treatment regime of Paccal Vet-CA1 by lowering the dose to reduce side effects and improve comfort for companion animals, the product will become far more attractive to veterinarians and pet owners. . Says in order to achieve this goal, the Company has withdrawn its current label which is conditionally approved and plan to initiate a new study confirming the changed dosing regimen. .These strategic changes are expected to be implemented during 2017.  Full Article

Oasmia Pharmaceutical Q1 loss per share SEK 0.34
Friday, 2 Sep 2016 09:36am EDT 

Oasmia Pharmaceutical AB:Q1 loss per share SEK 0.34.  Full Article

Oasmia Pharmaceutical Q1 operating loss narrows
Friday, 2 Sep 2016 02:17am EDT 

Oasmia Pharmaceutical AB : Q1 consolidated net sales amounted to TSEK 36 compared to TSEK 219 in Q1 previous year .Q1 operating loss was TSEK 32,343 compared to a loss of TSEK 37,819 in Q1 previous year.  Full Article

Oasmia names Fredrik Gynnerstedt as new Chief Financial Officer
Wednesday, 31 Aug 2016 02:37am EDT 

Oasmia Pharmaceutical AB :Says appoints Fredrik Gynnerstedt as Chief Financial Officer.  Full Article

Oasmia Pharmaceutical Q4 operating loss widens
Friday, 3 Jun 2016 02:15am EDT 

Oasmia Pharmaceutical AB : Q4 operating loss was TSEK 30,619 compared to a loss of TSEK 28,250 in Q4 previous year .Q4 consolidated net sales amounted to TSEK 59 compared to TSEK 36 in Q4 previous year.  Full Article

Oasmia Pharmaceutical AB announces positive overall survival results from Phase III study of apealea/paclical for treatment of ovarian cancer
Wednesday, 27 Apr 2016 07:00am EDT 

Oasmia Pharmaceutical AB:Announces positive overall survival results from Phase III study of apealea/paclical for treatment of ovarian cancer.Says Overall Survival data from Phase III study meets endpoint and demonstrates non-inferiority favoring Paclical/Apealea.Says will form basis for application seeking marketing approval in the United States anticipated for the late 2016 or early 2017.  Full Article

Oasmia completes private placements of SEK 45.5 mln
Friday, 15 Apr 2016 03:06am EDT 

Oasmia Pharmaceutical AB:Says successfully completes private placements of new convertible instruments and new shares in the total amount of 45.5 million Swedish crowns.Says intends to use the proceeds from the Private Placements to strengthen the working capital as well as finance the continued operations and further development of additional human and veterinary products based on the XR-17 technology.  Full Article

More From Around the Web

BRIEF-Oasmia completes private placements of new convertibles

* Says successfully completes private placements of New convertibles in the total amount of SEK 42 million with conversion rate Of SEK 5.95 Source text for Eikon: Further company coverage: (Stockholm Newsroom)

No consensus analysis data available.